About
Technology
Issues
FAQ
Links
Official Page
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.